PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Oncology

Manuscript NO: 57419

Title: Efficacy and safety of anti-PD-1/anti-PD-L1 antibody therapy in the treatment of advance gastric cancer or gastroesophageal junction cancer: A meta-analysis

Reviewer's code: 05207387

Position: Editorial Board

Academic degree: DSc, PhD

Professional title: Professor

Reviewer's Country/Territory: South Korea

Author's Country/Territory: China

Manuscript submission date: 2020-06-09

Reviewer chosen by: AI Technique

Reviewer accepted review: 2020-06-10 06:51

Reviewer performed review: 2020-06-12 10:24

Review time: 2 Days and 3 Hours

Scientific quality	[ ] Grade A: Excellent [Y] Grade B: Very good [ ] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Language quality	[ ] Grade A: Priority publishing [Y] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [ ] Accept (General priority) [Y] Minor revision [ ] Major revision [ ] Rejection
Re-review	[ ] Yes [Y] No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [ ] Onymous Conflicts-of-Interest: [ ] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

Thanks for recommending me as a reviewer. The purpose of this meta-study is to comprehensively evaluate the efficacy and safety of anti-PD-1/anti-PD-L1 antibody therapy in treatment of advanced GC/GEJC patients. The study was well written overall. If some changes are made, the quality of the study will be higher. 1. Introduction: If you describe the theoretical background in more detail in the Introduction section, it will help you understand. In particular, "efficacy and safety of anti-PD-1/anti-PD-L1 antibody therapy" should provide sufficient theoretical background for readers' understanding. 2. page 4: Inclusion and exclusion criteria need more specific explanation. 3. page 4: The author stated that he used "MeSHs headings" to search the literature. However, there is no "MeSHs headings" in the search terms. Did the author remove the notation "MeSHs headings"? 4. The statistical method of meta-analysis is appropriate. 5. page 5: "3.3Quality assessment of included studies": "Quality assessment of included studies" is as important as meta-analysis. Readers are likely to be interested in the results of the "Quality assessment of included studies". I suggest giving the author more specific information about the "Quality assessment of included studies". 6. In the "Discussion" section, the author should refer to the previous study and explain in more detail the mechanism of "efficacy and safety of anti-PD-1/anti-PD-L1 antibody therapy".